Cyclodextrin

DEXSORB® APPROVED TO TREAT PFAS IN MASSACHUSETTS

Retrieved on: 
Thursday, March 14, 2024
RCRA, Environmental protection, Cyclodextrin, Attention, PFNA, PFAS, PFOS, Environment, Bartlett, City, Cancer, PFOA, Groundwater, Carbon, MMCL, Drinking, NSF, EPA, Water, Immune system, Safety, AECOM, DWP, Perfluorohexanesulfonic acid, Drinking water, Cosmetics

In October 2020, MassDEP established the Massachusetts Maximum Contaminant Level (MMCL), a PFAS public drinking water standard, at 20 parts per trillion (ppt) for the sum of concentrations of six PFAS chemicals: PFOS, PFOA, PFHxS, PFNA, PFHpA, and PFDA.

Key Points: 
  • In October 2020, MassDEP established the Massachusetts Maximum Contaminant Level (MMCL), a PFAS public drinking water standard, at 20 parts per trillion (ppt) for the sum of concentrations of six PFAS chemicals: PFOS, PFOA, PFHxS, PFNA, PFHpA, and PFDA.
  • Made with renewable cyclodextrins, the media features 0.78 nanometer adsorbent cups with molecular selectivity for PFAS.
  • The media is certified to NSF/ANSI/CAN 61 standards, validating its safety for use to treat public drinking water.
  • The ability to regenerate DEXSORB and isolate PFAS waste in concentrated form makes it highly compatible with destruction technologies."

Magic Rings -- How to Solve Your Parenteral Formulation Challenges with Cyclodextrins, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Thursday, October 5, 2023
Cyclodextrin, Doctor of Philosophy, Solubility, Route of administration, Excipient, Research, R, Generic drug, Parenteral nutrition

TORONTO, Oct. 5, 2023 /PRNewswire-PRWeb/ -- Discover an innovative webinar delving into the use of cyclodextrins in parenteral drugs. Parenteral injection is often the best administration route for some active pharmaceutical ingredients. Developing these formulations is a complex task that requires safe, functional, high-quality ingredients. Cyclodextrins are excipients that enable parenteral drug development by increasing their aqueous solubility, increasing their chemical stability and improving their bioavailability through the formation of drug-cyclodextrin complexes.

Key Points: 
  • The speakers will also share a rational step-by-step approach to optimizing drug solubilization and stabilization in parenteral formulations.
  • TORONTO, Oct. 5, 2023 /PRNewswire-PRWeb/ -- Discover an innovative webinar delving into the use of cyclodextrins in parenteral drugs.
  • Their usage in parenteral drug formulations is frequently preferred over other solubilizing techniques due to their favorable toxicological and pharmacokinetic profiles.
  • Join this webinar to gain insights into cyclodextrins in parenteral drugs and the mechanisms of drug-cyclodextrin complex formation.

Roquette Announces Strategic Investment and Innovation Agreement with Beren Therapeutics P.B.C.

Retrieved on: 
Tuesday, May 23, 2023
Biotechnology, Pharmaceutical, Health, Fourth Estate Public Benefit Corporation, Drug development, CMC, Professional corporation, Cyclodextrin, Multimedia, Research, Chemistry, Strategic management, Patient, Ecosystem, Therapy, Pharmaceutical industry, Management, Roquette

Roquette, a leading provider of pharmaceutical excipients and global leader in plant-based ingredients, is pleased to announce a strategic investment with Beren Therapeutics P.B.C., and the launch of an innovation agreement to expand the full potential of Beren’s cyclodextrin technologies and their medicinal applications.

Key Points: 
  • Roquette, a leading provider of pharmaceutical excipients and global leader in plant-based ingredients, is pleased to announce a strategic investment with Beren Therapeutics P.B.C., and the launch of an innovation agreement to expand the full potential of Beren’s cyclodextrin technologies and their medicinal applications.
  • View the full release here: https://www.businesswire.com/news/home/20230523005131/en/
    Beren is a vertically integrated biopharmaceutical company focused on addressing the world’s most significant health challenges.
  • Roquette recognizes the revolutionary potential of Beren’s research to transform the market and the lives of millions of patients worldwide.
  • To learn more about Roquette’s latest strategic partnerships and its wider cyclodextrins portfolio, visit: www.roquette.com .

Pharmaceutical Excipients Global Market Report 2022: Use of Nanotechnology to Improve Excipients Capabilities to Reshape Sector - ResearchAndMarkets.com

Retrieved on: 
Wednesday, December 28, 2022
Health, Pharmaceutical, Cancer, Excipient, Government, Ministry, Protein, Infection, COVID-19, Compound, Syringe, API, Growth, Tablet, Cellulose, Prescription, Capsule, Safety, OTC, Sugar, Cyclodextrin, FDA, Food and Drug Administration, Nanotechnology, Sale, Lipid, Pharmaceutical industry, Fine chemical, Generic drug, Vaccine, Food, Fertilizer

The "Pharmaceutical Excipients Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Type, Clinical Indication, Functionality, Application, End User" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Pharmaceutical Excipients Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Type, Clinical Indication, Functionality, Application, End User" report has been added to ResearchAndMarkets.com's offering.
  • The report highlights trends prevailing in the market and factors driving the market growth.
  • Additionally, the use of nanotechnology to improve excipients capabilities is likely to emerge as a significant trend in the market during the forecast period.
  • Based on clinical indication, the global pharmaceutical excipients market is segmented into cancer, metabolic, infectious diseases, dental, ophthalmic, gene therapies, and others.

Ceapro Inc. Announces Positive Data from Bioavailability Studies Evaluating CoQ10 Formulations Impregnated with PGX-Processed Carriers

Retrieved on: 
Thursday, October 13, 2022
Microbiology, Technology, Animal, Cyclodextrin, IAL, Engineering, MBA, Tissue, Innovation, University, Food, Company, Marketing, Department, CEO, Nutritional science, Absorption, Research, Biopolymer, Triolein, Human, Biochemistry, Pharmaceutical industry, Coenzyme Q10

Additionally, we are excited about some data strongly suggesting that we have a slow release formulation when combining i(AL+YBG) with CoQ10 (8-12 hours), which would be a first-in-class product.

Key Points: 
  • Additionally, we are excited about some data strongly suggesting that we have a slow release formulation when combining i(AL+YBG) with CoQ10 (8-12 hours), which would be a first-in-class product.
  • The license from U of A provides Ceapro with exclusive worldwide rights in all industrial applications.
  • Ceapro adds further value to its extracts by supporting their use in cosmeceutical, nutraceutical, and therapeutics products for humans and animals.
  • For more information on Ceapro, please visit the Companys website at www.ceapro.com .

Insights on the Pharmaceutical Drug Delivery Global Market to 2027 - by Route of Administration, Application, End-user and Region - ResearchAndMarkets.com

Retrieved on: 
Monday, July 25, 2022
Technology, Medical Devices, Medical Supplies, Packaging, Chemicals, Plastics, Other Technology, Health Technology, Manufacturing, Pharmaceutical, Health, Brain, Time, Leishmaniasis, Coronavirus, Nanoparticle, Toxicity, Administration, Cyclodextrin, Industry, MI, Prodrug, CNS, Safety, COVID-19, Microparticle, Cancer, Lung, Central nervous system, Gel, Liposome, Efficiency, Prevalence, Pharmaceutical industry, Generic drug, Potash

At present, different types of drug delivery systems are available for the release of various therapeutic agents.

Key Points: 
  • At present, different types of drug delivery systems are available for the release of various therapeutic agents.
  • Key Questions Answered in This Report:
    How has the global pharmaceutical drug delivery market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global pharmaceutical drug delivery market?
  • What is the structure of the global pharmaceutical drug delivery market and who are the key players?

Cyclopure Announces Purefast™ Home Filter for PFAS!

Retrieved on: 
Thursday, April 7, 2022
Zero, National Science Foundation, Department of Defense Cyber Crime Center, PFOS, NSF International, SRP, Government, PFNA, PFOA, Multimedia, GenX, Science, Environmental factor, PFAS, Environment, National Institute, Filter, View, Cyclodextrin, Environmental monitoring, National Institute of Environmental Health Sciences, Defense, Department, Michele Cassou, NSF, Biophysical environment, Water, Bottled water

SKOKIE, Ill., April 7, 2022 /PRNewswire/ -- Cyclopure Inc. today announced the commercial launch of its Purefast filters for PFAS removal from tap water.

Key Points: 
  • SKOKIE, Ill., April 7, 2022 /PRNewswire/ -- Cyclopure Inc. today announced the commercial launch of its Purefast filters for PFAS removal from tap water.
  • The home filter is compatible for use with Brita countertop pitchers, and has been certified by NSF International for PFAS removal.
  • "We are thrilled to bring Purefast to market, a first-ever product for use with countertop pitchers to remove PFAS," said Cyclopure CEO Frank Cassou.
  • Each Purefast filter comes with prepaid packaging to return used cartridges to our lab for safe disposal.

DGAP-News: Wacker Chemie AG: After Record Sales in 2021, WACKER Continues its Growth in 2022

Retrieved on: 
Tuesday, March 15, 2022
BUT, Growth, Annual report, COME, Solution, Face, Wacker Chemie, Vaccine, CIS, Tax, WITH, EBIT, Powder, Record sales, Public expenditure, Depreciation, Goal, Sympathy, CEO, Cyclodextrin, SALES, Electricity, Shock, Capital market, Policy, Speciality chemicals, Security (finance), Holding company, Pharmaceutical industry, Lithium, Renewable energy, Fine chemical, EBITDA, Group

Wacker Chemie AG: After Record Sales in 2021, WACKER Continues its Growth in 2022

Key Points: 
  • Wacker Chemie AG: After Record Sales in 2021, WACKER Continues its Growth in 2022
    The issuer is solely responsible for the content of this announcement.
  • Higher prices, higher volumes for chemical business and positive product-mix effects across all divisions will be the main growth drivers.
  • Overall, WACKER expects to post Group sales of about 2 billion in Q1 2022 (Q1 2021: 1.36 billion).
  • WACKER SILICONES expects to post sales of around 3 billion and WACKER POLYMERS approximately 2 billion.

Global Encapsulation Market Forecast to 2028 - COVID-19 Impact and Analysis - ResearchAndMarkets.com

Retrieved on: 
Thursday, February 3, 2022
Food, Beverage, Retail, Growth, Polymer, Starch, Cyclodextrin, Water, COVID-19, CAGR, Fructose, Solubility, Urban, Carbohydrate, Organic compound, Industry, Lipid, Protein, Chitosan

The "Encapsulation Market Forecast to 2028 - COVID-19 Impact and Global Analysis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Encapsulation Market Forecast to 2028 - COVID-19 Impact and Global Analysis" report has been added to ResearchAndMarkets.com's offering.
  • The global encapsulation market is expected to grow from US$ 35,113.49 million in 2021 to US$ 80,071.65 million by 2028; it is estimated to grow at a CAGR of 12.5% from 2021 to 2028.
  • Based on coating material, the Encapsulation market is segmented into polymers, gums and resins, lipids, carbohydrates and proteins.
  • The Encapsulation market in Asia Pacific is expected to grow at the highest CAGR during the forecast period.

DGAP-News: Wacker Chemie AG: WACKER Sets New Corporate Sustainability Goals

Retrieved on: 
Monday, December 20, 2021
Zero, Hydrogen, Climate, Wacker Chemie, MOST, Charcoal, Burghausen, Powder, Electricity, Feasibility study, TO, Race, VCI, CCS, Wind, CCU, Chemical industry, Time, SALES, Coal, Temperature, Silicon, Acetic acid, CEO, Paris Agreement, Goal, Capital market, Climate change, Biomass, Water, Methanol, UN, Silicone, CO2, Paris, Fermentation, Semiconductor, Board of directors, Cyclodextrin, Food, Carbon, Renewable energy, Yvonne von Hartel

WACKER is striving to ensure that its entire product portfolio meets defined sustainability criteria by 2030 (previously: 90 percent).

Key Points: 
  • WACKER is striving to ensure that its entire product portfolio meets defined sustainability criteria by 2030 (previously: 90 percent).
  • It also expects all its key suppliers to meet defined sustainability standards by 2030 (previously: 90 percent).
  • During the same period, it expects a 25-percent drop in emissions relating to upstream products used by WACKER.
  • A new goal refers to specific water withdrawal, which WACKER aims to reduce by 15 percent by 2030.